HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) is now available in the province of Québec, Canada.
“The availability of a new treatment option to help health care professionals and patients prevent HAE attacks is an important milestone and great news for the HAE patient community,” said Charles St-Pierre, President of the AOHQ patient group.
CSL Behring Canada is also committed to help patients get access to training for the administration of HAEGARDA via CSL Behring PLUS+ program that offers a wide array of services, and educational materials. Patients can ask their Healthcare professionals to enroll them in the program at any time.
(Source: CSL Behring)